Tenofovir disoproxil fumarate-300mg + Efavirenz-600mg

What is Tenofovir disoproxil fumarate-300mg + Efavirenz-600mg?

Tenofovir disoproxil fumarate-300mg + Efavirenz-600mg is a combination antiretroviral medication designed for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. This fixed-dose tablet integrates two essential drugs: tenofovir disoproxil fumarate, a nucleotide reverse transcriptase inhibitor, and efavirenz, a non-nucleoside reverse transcriptase inhibitor. Together, they suppress viral replication, helping maintain low viral loads and support immune function. It is taken once daily, typically on an empty stomach, and is intended for use as part of a complete HIV treatment regimen under the guidance of a healthcare provider.

Key features

• Fixed-Dose Combination — Merges two antiretrovirals in one tablet for simplified dosing.
• Once-Daily Use — Supports adherence with convenient daily administration.
• Viral Suppression — Targets HIV-1 replication at the transcription level.
• Oral Tablet Form — Easy-to-swallow, film-coated tablet for consistent delivery.
• Established Efficacy — Based on long-standing clinical use in HIV management.
• Prescription Required — Ensures medical oversight for safe and appropriate use.

Who is Tenofovir disoproxil fumarate-300mg + Efavirenz-600mg for?

This medication is intended for adults diagnosed with HIV-1 infection who require antiretroviral therapy. It is especially suitable for patients new to treatment or those transitioning to a simpler regimen. Not recommended for individuals with hypersensitivity to efavirenz or tenofovir, or those with severe kidney or liver impairment. Pregnant women or those planning pregnancy should consult a physician due to efavirenz-related risks.

How does Tenofovir disoproxil fumarate-300mg + Efavirenz-600mg compare?

Compared to other HIV regimens, this combination offers a cost-effective, once-daily option with proven long-term efficacy. While newer integrase inhibitor-based regimens may offer faster viral suppression and fewer side effects, this formulation remains a widely used backbone in resource-conscious settings. It lacks the convenience of single-tablet regimens containing three agents but provides reliable dual-action therapy when combined with other antiretrovirals.